Zenas BioPharma Q3 EPS Forecast Reduced by HC Wainwright

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Equities research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for Zenas BioPharma in a report released on Wednesday, August 13th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.08) per share for the quarter, down from their prior estimate of ($0.93). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. HC Wainwright also issued estimates for Zenas BioPharma’s Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.17) EPS, FY2026 earnings at ($3.69) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.85) EPS and FY2029 earnings at ($1.87) EPS.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.23).

Separately, Wedbush restated an “outperform” rating and issued a $35.00 target price on shares of Zenas BioPharma in a report on Thursday, May 15th.

Zenas BioPharma Stock Up 0.4%

NASDAQ:ZBIO opened at $16.82 on Friday. The stock has a 50 day moving average price of $12.74. Zenas BioPharma has a 52 week low of $5.83 and a 52 week high of $26.25. The firm has a market capitalization of $708.29 million and a P/E ratio of -4.74.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund acquired a new stake in Zenas BioPharma in the 1st quarter worth approximately $49,000. PNC Financial Services Group Inc. lifted its holdings in Zenas BioPharma by 41.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after purchasing an additional 2,679 shares during the last quarter. Sei Investments Co. acquired a new stake in Zenas BioPharma in the 2nd quarter worth approximately $118,000. Intech Investment Management LLC lifted its holdings in Zenas BioPharma by 13.9% in the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock worth $128,000 after purchasing an additional 1,607 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after buying an additional 3,412 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.